Alireza MANUCHEHRI,Klaus DUGI,Peter EICKELMANN,Leo THOMAS
申请号:
US14881465
公开号:
US20160030385A1
申请日:
2015.10.13
申请国别(地区):
US
年份:
2016
代理人:
摘要:
The present invention is directed to a pharmaceutical composition comprised of one or more SGLT-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class I obesity, class II obesity, class III obesity, visceral obesity and abdominal obesity, and metabolic syndrome.